Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Total Current Liabilities (2018 - 2025)

Historic Total Current Liabilities for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $17.0 billion.

  • Takeda Pharmaceutical's Total Current Liabilities rose 2288.4% to $17.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $17.0 billion, marking a year-over-year increase of 2288.4%. This contributed to the annual value of $16.5 billion for FY2025, which is 259.11% up from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Total Current Liabilities of $17.0 billion as of Q4 2025, which was up 2288.4% from $14.5 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Total Current Liabilities ranged from a high of $18.8 billion in Q1 2023 and a low of $13.8 billion during Q4 2024
  • Moreover, its 5-year median value for Total Current Liabilities was $16.2 billion (2023), whereas its average is $16.4 billion.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Total Current Liabilities tumbled by 1745.88% in 2021, and later surged by 2288.4% in 2025.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Total Current Liabilities stood at $15.9 billion in 2021, then fell by 0.53% to $15.8 billion in 2022, then dropped by 2.49% to $15.4 billion in 2023, then fell by 10.62% to $13.8 billion in 2024, then grew by 22.88% to $17.0 billion in 2025.
  • Its last three reported values are $17.0 billion in Q4 2025, $14.5 billion for Q3 2025, and $15.0 billion during Q2 2025.